The Claim
In aged female 3xTg mice, 7 days of istradefylline treatment is associated with a 38% reduction in cortical amyloid precursor protein (APP) levels and a 28% reduction in total tau protein, resulting in levels comparable to those in young 3xTg mice.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In aged female 3xTg mice, 7 days of istradefylline treatment reduces cortical amyloid precursor protein levels by 38% and total tau protein levels by 28%, bringing them to levels observed in young 3xTg mice.
See the scientific wording
In aged female 3xTg mice, 7 days of istradefylline treatment was associated with a 38% reduction in cortical amyloid precursor protein (APP) levels and a 28% reduction in total tau protein, bringing them to levels similar to those in young 3xTg mice, suggesting that A2A receptor blockade may reduce key Alzheimer’s-related proteinopathies in this model.
Blocking a specific brain receptor improves blood flow and seals leaks in the brain's protective barrier, which reduces the buildup of two harmful proteins linked to Alzheimer's disease.
What the research says
1 studyIn older mice with Alzheimer’s-like brain changes, a drug called istradefylline helped lower two harmful proteins (APP and tau) that clump together in the brain, bringing them down to levels seen in young mice. This suggests the drug might help slow Alzheimer’s damage.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.